| 博纳吐单抗治疗急性淋巴细胞白血病的研究进展 |
| |
| 引用本文： | 邬芝雅,谷帅,凡学婷,冯继锋.博纳吐单抗治疗急性淋巴细胞白血病的研究进展[J].中国肿瘤临床,2021,48(11):576-580. |
| |
| 作者姓名： | 邬芝雅 谷帅 凡学婷 冯继锋 |
| |
| 作者单位： | 1.南京医科大学附属肿瘤医院，江苏省肿瘤医院，江苏省肿瘤防治所 （南京市210009） |
| |
| 摘 要： | 近年来，随着免疫治疗和造血干细胞移植技术（hematopoietic stem cell transplantation，HSCT）的发展，急性淋巴细胞白血病（acute lymphoblastic leukemia，ALL）的缓解率逐渐升高，但复发难治性ALL的预后仍旧很差。博纳吐单抗（blinatumomab）作为一个新型的CD3和CD19双特异性抗体在复发难治性ALL中均获得较好的疗效，并于2014年12月被美国食品药品监督管理局（FDA）批准用于复发难治性急性B淋巴细胞白血病（B-cell acute lymphoblastic leukemia，B-ALL）的治疗。博纳吐单抗单药治疗初治ALL及联合化疗药物、酪氨酸激酶抑制剂治疗ALL均可改善患者生存期。本文主要围绕博纳吐单抗的临床试验、不良反应等方面的最新研究进行阐述。
|
| 关 键 词： | 博纳吐单抗 双特异性抗体 急性淋巴细胞白血病 临床研究 |
| 收稿时间： | 2020-12-28 |
Research progress on blinatumomab in the treatment of acute lymphoblastic leukemia |
| |
| Institution: | 1.The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing 210009, China2.Nanjing Medical University, Nanjing 210029, China3.School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, China |
| |
| Abstract: | The remission rate of acute lymphoblastic leukemia (ALL) has gradually increased with the progression of immunotherapy and hematopoietic stem cell transplantation (HSCT). While the prognosis of relapsed or refractory ALL is still poor, blinatumomab, a bispecific CD19/CD3 T-cell engager, has been approved for treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) because of its efficacy. A number of clinical trials have demonstrated the efficacy of this agent in the frontline setting and in combination regimens such as cytotoxic chemotherapy and tyrosine kinase inhibitor. In this paper, the clinical trials and adverse events of the latest research progress on blinatumomab are reviewed. |
| |
| Keywords: | |
|
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
| 点击此处可从《中国肿瘤临床》下载免费的PDF全文 |
|
